Bio-Rad dPCR Partnership
Cancer
Key Facts
About NuProbe
NuProbe is a privately held, US-based company founded in 2016 with a mission to improve the analytical sensitivity of DNA biomarker detection for cancer research and diagnostics. Its core technology platform includes Blocker Displacement Amplification (BDA) for rare allele enrichment on PCR/digital PCR and Quantitative Amplicon Sequencing (QASeq) for highly multiplexed, UMI-based NGS assays. The company has secured a significant $50M funding round, entered a key licensing agreement with Bio-Rad, and operates with a dual business model of developing research-use assays and providing custom assay development services to biopharma. NuProbe is positioned to address the growing need for sensitive liquid biopsy and tissue-based testing in oncology.
View full company profileTherapeutic Areas
Other Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| Not Specified (Oncology Focus) | Narwhal Bio | Pre-clinical |
| EDM Platform for Genetic Medicine | Coastar Therapeutics | Pre-clinical |
| CO-1 | Caedo Oncology | Pre-clinical |
| Anti-CD99 monoclonal antibody | Caedo Oncology | Discovery/Pre-clinical |
| Anti-HLA class I monoclonal antibody | Caedo Oncology | Discovery/Pre-clinical |
| Triapine® | Nanopharmaceutics | Clinical |
| Ammonium Tetrathiomolybdate | Nanopharmaceutics | Clinical |
| Aza-TdC | Nanopharmaceutics | Clinical |
| Undisclosed Oncology Program(s) | Cell BioEngines | Phase 1 |
| No-alpha IL-2 Mutein | SarcoMed USA | Pre-clinical |
| PMIS Therapeutic | NaturemiRI | Preclinical/Clinical (unspecified) |
| AUM302 (formerly IBL-302) | Inflection Biosciences | Pre-clinical (partnered) |